14:48 , Aug 21, 2019 |  BC Innovations  |  Distillery Therapeutics

Bivalent degraders of HCV NS3/4A protease complex for HCV infection

DISEASE CATEGORY: Infectious disease INDICATION: Hepatitis C virus (HCV) Bivalent small molecules targeting the HCV NS3/4A protease complex and CRBN, which recruits E3 ubiquitin ligase and induces proteasomal degradation, could treat HCV. The molecules were...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
18:07 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV) In vitro and cell culture studies identified analogs of the HCV NS3/4A protease complex inhibitor grazoprevir that could help treat drug-resistant HCV infections. Chemical synthesis and testing of grazoprevir analogs...
07:00 , Sep 7, 2015 |  BioCentury  |  Strategy

Back to School: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-I trial in 311 treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax and Exviera dasabuvir with and without ribavirin for 12 weeks led to SVR4...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-II trial in 148 treatment-experienced patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax and Exviera dasabuvir with ribavirin for 12 weeks led to an SVR4 and...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Exviera dasabuvir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-I trial in 311 treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax ombitasvir/paritaprevir/ritonavir and Exviera with and without ribavirin for 12 weeks led to SVR4...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Exviera dasabuvir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-II trial in 148 treatment-experienced patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax ombitasvir/paritaprevir/ritonavir and Exviera with ribavirin for 12 weeks led to an SVR4 and...
08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Shooting F-stars

F-star Alpha Ltd. 's deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

Telavic telaprevir regulatory update

Mitsubishi Tanabe said Japan approved a regulatory application to expand the label of Telavic telaprevir to include treatment of chronic HCV genotype 2 infection. Mitsubishi Tanabe markets the small molecule HCV NS3/4A protease inhibitor in...